Brooks Gentry

February 20, 2018

Based on UAMS Research, InterveXion Wins Grants, Partners with BioVentures’ Help

Ben Boulden

Misty Stevens demonstrates one of the lab procedures InterveXion uses in the development of the monoclonal antibody it is studying for possible future use in the treatment of methamphetamine addiction.

Feb. 20, 2018 | Truly good ideas like the one around which InterveXion was built have staying power. Since InterveXion was established as a company in 2004, granting agencies and others have continued to value both the company and its mission. BioVentures from the first saw merit in the new treatment for methamphetamine abuse developed…

December 23, 2013

Medical Showcase Events Becoming Part of Research Culture

Ben Boulden

Dec. 23, 2013 | Fifth in a continuing series of such events, the “Showcase of Medical Discoveries: A Focus on Substance Abuse” on Dec. 5 pulled in dozens of UAMS researchers, physicians, faculty and students despite the onset of wintry weather just an hour before its start.